The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
HRS-8080, an oral selective estrogen receptor degrader (SERD), in ER+/HER2- advanced breast cancer (aBC) with ESR1 mutations (ESR1m): Results from a first-in-human phase 1 trial.
 
Zefei Jiang
No Relationships to Disclose
 
Ting Luo
No Relationships to Disclose
 
Haifeng Liu
No Relationships to Disclose
 
Xu Wang
No Relationships to Disclose
 
Tao Wang
No Relationships to Disclose
 
Huihui Li
No Relationships to Disclose
 
Jin Yang
No Relationships to Disclose
 
Yang Li
No Relationships to Disclose
 
Min Yan
No Relationships to Disclose
 
Yongmei Yin
No Relationships to Disclose
 
Jing Yao
No Relationships to Disclose
 
Jingruo Li
No Relationships to Disclose
 
Yueyin Pan
No Relationships to Disclose
 
Xiaoyu Zhu
Employment - Hengrui Pharmaceutical
 
Wenjie Xin
Employment - Hengrui Pharmaceutical
 
Dapeng Zhang
Employment - Hengrui Pharmaceutical